Recent combinations of chemotherapy have significantly improved the response rate and survival time for patients with metastatic colorectal cancer.
Jean-yves Douillard, MD, PhD
Advertisement
Articles by Jean-yves Douillard, MD, PhD
Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU.
Advertisement
Latest Updated Articles
- Update on European Adjuvant Trials With Irinotecan for Colorectal Cancer
Published: April 1st 2002 | Updated:
- Irinotecan and High-Dose Fluorouracil/Leucovorin for Metastatic Colorectal Cancer
Published: December 3rd 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
4
Classifying High-Risk Patients With NDMM
5
